Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02816619
Other study ID # CHU-0265
Secondary ID 2016-A00040-51
Status Recruiting
Phase N/A
First received June 3, 2016
Last updated June 27, 2016
Start date March 2016
Est. completion date September 2018

Study information

Verified date June 2016
Source University Hospital, Clermont-Ferrand
Contact Patrick LACARIN
Phone 04 73 75 11 95
Email placarin@chu-clermontferrand.fr
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

There is growing interest for physical activity in Parkinson's disease in order to improve mobility and function of these patients. It seems from previous studies that difficulty, intensity and specificity of physical exercises are important parameters conditioning the effect of physical activity on cerebral plasticity and clinical improvement.

Thus, the aim of this study is to evaluate the benefits of a Personalized Physical Activity coaching program, including scheduled and frequent follow up associated with progressive readaptation of exercise intensity depending on individual performances (during 3 months), versus free practice of physical activity in Parkinson's disease.


Description:

Type of study: a randomized, single-blind, parallel-group, controlled clinical trial.

Number of centers: 1 (Clermont-Ferrand)

Patients

Patients eligible for inclusion will be randomized to one of the two groups:

- APA + : patients will beneficiate of Personalized Physical Activity coaching program during 3 months (1 hour, twice by week, during 3 months)

- APA- : patients will do free practice of physical activity during 3 months.

Study Performance Patients will be evaluated 3 times : at J0 (baseline, V1), 3 months after Personalized Physical Activity coaching program (J0+3M, V2), and 3 months after the end of the Personalized Physical Activity coaching program (J0+6M)

V1:

- Signature of an informed consent form.

- Demographic and clinical characteristics (sex, age, disease duration, treatments).

V1, V2, V3

- Neurological evaluation (Unified Parkinson Disease Rating Scale part III score)

- Evaluation of quality of life (Parkinson's Disease Questionnaire 39-item version (PDQ-39), participation to Daily life activities (Lawton and Brody Activities of Daily Living scale (IADL questionnaire25)

- Evaluation of performances for specific tests for balance (stabilometry), muscular strength (isometry)

- Evaluation of cardiorespiratory function (VO2pic et 6 min Walk Test)

- Evaluation of body composition (lean body mass/fat mass) with DEXA.

- Dropout rates at V2 and V3

- Evaluation of the activity with the eMOUVE application in a subgroup of patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Clinical criteria for Parkinson's disease

- Men or women aged from 18 to 80 years old.

- Social security coverage.

- Ability to provide informed consent.

Exclusion Criteria:

- neurological disease other than Parkinson's disease

- severe depression (Beck Depression Inventory>37) or psychiatric comorbidities (UPDRS I )

- significant cognitive impairment (MoCA<24)

- orthopedic impairment with functional restriction

- contraindication to physical exercise

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Personalized Physical Activity coaching program

Free practice of physical activity


Locations

Country Name City State
France CHU Clermont-Ferrand Clermont-Ferrand

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand AME2P, UFR STAPS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline of the Unified Parkinson Disease Rating Scale part III score at +3months No
Secondary Change from baseline of Parkinson's Disease Questionnaire 39-item version score at +3months No
Secondary Change from baseline of the Lawton and Brody Activities of Daily Living scale score at +3months No
Secondary Change from baseline of the percentage of sedentarity, mild, moderate and intense activity using the eMOUVE application at +3months No
Secondary Change from baseline of percentage of sedentarity, mild, moderate and intense activity using the eMOUVE application at + 6 months No
Secondary Change from baseline of balancing abilities measured by stabilometry at +3months No
Secondary Change from baseline of balancing abilities measured by stabilometry at + 6 months No
Secondary Change from baseline of muscular strength measured with isometric test at +3months No
Secondary Change from baseline of muscular strength measured with isometric test at +6months No
Secondary Change from baseline of VO2pic at +3months No
Secondary Change from baseline of VO2pic at + 6 months No
Secondary Change from baseline of the 6 min Walking Test score at +3 months No
Secondary Change from baseline of the 6 min Walking Test score at + 6 months No
Secondary Change from baseline of fat and lean body mass measured by DEXA at +3 months. No
Secondary Change from baseline fat and lean body mass measured by DEXA at +6 months. No
Secondary dropout rates at +3 months No
Secondary dropout rates at +6 months No
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Completed NCT02874274 - Vaccination Uptake (VAX) in PD N/A
Completed NCT02939391 - A Study of KW-6356 in Subjects With Early Parkinson's Disease Phase 2